COVAXIN

Photo: The New Indian

Bharat Biotech Concluded Phase III Clinical Development

Bharat Biotech International said that controlled clinical studies on participants showed that BBV154 (the intranasal vaccination) was safe, well-tolerated, and immunogenic on August 15. A pre-fusion stabilized spike protein is present in the recombinant replication-deficient adenovirus vector vaccine known as BBV154. Phase I and II clinical studies conducted previously on this vaccine candidate had positive outcomes. BBV154 has been created… read-more

Mon, 15 Aug 2022 - 06:30 PM / by Vidhi Jhunjhunwala

Tags: Bharat biotech, phase iii, clinical development, covid booster dose, Covid-19

Courtesy: ANI